Innovation Pharmaceuticals Inc (IPIX)

[georgejjl]

For the Phase 2 Otezla trial CC-10004-PSOR-004

...It is important to note that the proportion of subjects achieving PASI-75 (30%) is similar to the 24.3% seen in Study CC-10004-PSOR-003, where subjects could not enter the trial if they had failed therapy with cyclosporine pr biologic therapy....

https://media.celgene.com/content/uploads/CC-10004-PSOR-004-Synopsis-Redacted.pdf

Expect much better results from Prurisol 150 mg BID and 200 mg BID.

https://clinicaltrials.gov/ct2/show/NCT02949388?term=NCT02949388&rank=1

Good luck and GOD bless,

George